1 / 21

Patient Interest Seminar 21 st May

Patient Interest Seminar 21 st May . Dr. Andrew Power Vice Chair New Drugs Sub group. Objectives. SMC processes NDC & SMC Health Board Formulary processes QALY tables. Scottish Medicines Consortium. SMC – multidisciplinary (30) Physicians, pharmacists, health economists

eliora
Télécharger la présentation

Patient Interest Seminar 21 st May

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patient Interest Seminar 21st May Dr. Andrew Power Vice Chair New Drugs Sub group

  2. Objectives SMC processes NDC & SMC Health Board Formulary processes QALY tables

  3. Scottish Medicines Consortium

  4. SMC – multidisciplinary (30) Physicians, pharmacists, health economists NHS executives/finance managers Pharmaceutical industry nominees (ABPI) Public partners (3) PR, Scottish Government representatives NDC - clinical/scientific (15) Physicians, pharmacists, nurse, health economists, academics, industry nominees Including Pharmacy Assessment Team and Health Economics Team Composition

  5. Safety, quality and efficacy…

  6. SMC Remit • National consortium of representatives of local drug and therapeutic committees • Provide advice to NHS Boards on: • New medicines • New formulations of older medicines • Major new indications • Assess the need and clinical effectiveness including comparative efficacy • Assess the comparative cost-effectiveness • DO NOT assess safety

  7. Assessment process

  8. Scottish Medicines Consortium Produce a Detailed Advice Document (DAD) SMC may: Accept medicine for use in NHS Scotland Accepted for use in NHS Scotland (with restrictions) Not recommend for use in NHS Scotland All advice can be found on the SMC website: www.scottishmedicines.org.uk

  9. Count and annual share of SMC decisions, (excluding abbreviated and non-submissions)

  10. QALYs They are based on the number of years of life that would be added by the intervention. Each year in perfect health is assigned the value of 1.0 down to a value of 0 for death. If the extra years would not be lived in full health, for example if the patient would lose a limb, or be blind or be confined to a wheelchair, then the extra life-years are given a value between 0 and 1 to account for this.

  11. Cost-Effectiveness vs. Effectiveness DRUG B 96% Cure Rate £10 / patient DRUG A 90% Cure Rate £1 / patient With thanks to Dr. Andrew Walker, University of Glasgow

  12. Cost-Effectiveness vs. Effectiveness DRUG B 96% Cure Rate £10 / patient 96 cures / £1000 DRUG A 90% Cure Rate £1 / patient 900 cures / £1000

  13. Intervention Cost per QALY Stop smoking advice £270 Hip replacement £750 Heart transplant £5000 CABG £12600 MS treatment £40k to £600k

  14. New medicine / indication / formulation released onto market SMC review medicine SMC accept for use in NHS Scotland SMC do not accept for use in NHS Scotland Formulary and New Drugs Sub-committee (FND) consider medicine and make recommendation Medicine cannot be considered for addition to the GGC Formulary Manufacturer can make a re-submission to SMC Area Drug and Therapeutic Committee review FND recommendation Accepted for addition to Formulary (restrictions may apply) Rejected for addition to the Formulary Formulary Appeals Process Post SMC: local formulary process

  15. What is a formulary? • Generally, a list of medicine which the vast majority of prescribing should come from • May be a simple list • May include additional information and guidance • Can be applicable from anything from a single practice, to health board to country (e.g. BNF) • Formulary Management is the term given all processes linked to the Formulary including production, review and measurement of adherence

  16. Why produce a Formulary? • Promote cost-effective drug use • Maximise given resources • Limited resources • Increasing pressures • Minimise risk • Maximise procurement

  17. Fact or Fiction? • Medicines not accepted by SMC can not be prescribed by GPs • Fiction – GP in general should follow SMC advice, but in exceptional cases may prescribe ‘non-SMC’ medicines • In most health boards, GPs are able to appeal to have a medicine reconsidered for inclusion in the local formulary • Fact – most health boards have an appeal process that GPs can access • GPs are independent contractors and do not have to stick to any agreed local formulary • Fact with some fiction – GPs are independent contractors and can prescribe non-formulary medicines where they see fit, though they are requested to follow local formularies. • However, it should be noted that GPs are contracted to an NHS health board and widespread prescribing of medicines not accepted by SMC or non-Formulary without good reason could be deemed as inappropriate prescribing which may be considered a breach of contract.

  18. ADTC • ADTC consider SMC advice for local implementation • Consider local needs of the population • Opinions of relevant local clinicians and groups • Consider what is on Formulary already • Generally, approximately 85% of medicines accepted by SMC will be added to the Formulary

  19. Formulary adherence (GGC) • The Preferred List is a subset of about 350 medicines covering conditions managed in Primary Care • Current average adherence for the year is 74% • Adherence to the full formulary is unknown, but estimated at >90%

  20. Objectives SMC processes NDC & SMC Health Board Formulary processes QALY tables

More Related